Survivin gene expression in granulosa cells from infertile patients undergoing in vitro fertilization-embryo transfer.
OBJECTIVE
To evaluate survivin gene expression in granulosa cells from infertile patients and examine the relationship between survivin gene expression and infertile clinical background.


METHODS
Prospective study.


METHODS
IVF-ET program at Osaka Medical College.


METHODS
Twenty-eight patients underwent ovulation induction for IVF-ET performed because of tubal infertility, male factor infertility, or endometriosis.


METHODS
Granulosa cells obtained at oocyte retrieval were examined for survivin gene expression by quantitative reverse transcription-polymerase chain reaction.


METHODS
Hormone environment, number of oocytes, fertilization rate, high-quality embryo rate, pregnancy rate, and expression of survivin genes.


RESULTS
Survivin gene expression was detected in all granulosa cells. The gene expression levels of survivin in patients with endometriosis were significantly lower than those in patients with male factor infertility. The gene expression levels of survivin in total pregnant patients were higher than those in total nonpregnant patients and than those in the male factor infertility group, and there was no correlation between gene expression level and serum E(2) level.


CONCLUSIONS
Survivin may be used as an indicator of the success of IVF-ET, and the existence of endometriosis may elevate the apoptosis of granulosa cells.
Fujino
Kuniko
K
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka 569-8686, Japan. kuniko-mr@r9.dion.ne.jp
Yamashita
Yoshiki
Y
Hayashi
Atushi
A
Asano
Masako
M
Morishima
Shoko
S
Ohmichi
Masahide
M
D000328:Adult; D017209:Apoptosis; D015415:Biomarkers / Q000032:analysis; D004624:Embryo Transfer; D004715:Endometriosis / Q000150:complications / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D004958:Estradiol / Q000097:blood; D005184:Fallopian Tube Diseases / Q000150:complications / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D005260:Female; D005306:Fertilization; D005307:Fertilization in Vitro; D018507:Gene Expression Regulation, Developmental; D006107:Granulosa Cells / Q000737:chemistry* / Q000473:pathology; D006801:Humans; D007246:Infertility / Q000209:etiology / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D007248:Infertility, Male / Q000235:genetics / Q000378:metabolism / Q000628:therapy; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008869:Microtubule-Associated Proteins / Q000032:analysis* / Q000235:genetics; D009363:Neoplasm Proteins / Q000032:analysis* / Q000235:genetics; D054315:Oocyte Retrieval; D010062:Ovulation Induction; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D012333:RNA, Messenger / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077022:Survivin; D016896:Treatment Outcome
C107489:BIRC5 protein, human; D015415:Biomarkers; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D000077022:Survivin; D004958:Estradiol